IDUA and mucopolysaccharidosis type 1: Schuh and colleagues [44] administered nanoemulsions complexed with a plasmid encoding the IDUA (alpha-L-iduronidase) protein via nasal delivery, aiming to reach the brain for mucopolysaccharidosis type I (MPS I) gene therapy.